TRVN Stock - Trevena, Inc.
Unlock GoAI Insights for TRVN
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|
| Revenue | $3.13M | $-418,000 | $567,000 | $3.07M | $31,000 |
| Gross Profit | $1.46M | $-3,436,000 | $-387,000 | $2.89M | $-77,000 |
| Gross Margin | 46.6% | 822.0% | -68.3% | 94.1% | -248.4% |
| Operating Income | $-35,288,000 | $-56,375,000 | $-51,925,000 | $-29,485,000 | $-26,580,000 |
| Net Income | $-40,289,000 | $-53,667,295 | $-51,588,000 | $-29,369,000 | $-24,871,000 |
| Net Margin | -1289.2% | 12839.1% | -9098.4% | -957.0% | -80229.0% |
| EPS | $-3.16 | $-7.59 | $-7.90 | $-5.75 | $-7.65 |
Trevena, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV027 for the treatment of acute lung injury contributing to acute respiratory distress syndrome and abnormal blood clotting in patients with COVID-19; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain. The company has a collaboration with Imperial College London to evaluate Trv027 in Covid-19 patients. Trevena, Inc. was incorporated in 2007 and is headquartered in Chesterbrook, Pennsylvania.
Visit WebsiteEarnings History & Surprises
TRVNEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q4 2025 | Nov 5, 2025 | — | — | — | — |
Q3 2025 | Aug 11, 2025 | — | — | — | — |
Q2 2025 | May 29, 2025 | — | — | — | — |
Q2 2025 | May 6, 2025 | $-7.37 | — | — | — |
Q4 2024 | Nov 7, 2024 | $-7.32 | $-5.79 | +20.9% | ✓ BEAT |
Q3 2024 | Aug 8, 2024 | $-9.25 | $-5.75 | +37.8% | ✓ BEAT |
Q2 2024 | Apr 1, 2024 | $-13.00 | $-26.50 | -103.8% | ✗ MISS |
Q1 2024 | Mar 28, 2024 | $-0.38 | $-1.06 | -178.9% | ✗ MISS |
Q4 2023 | Nov 14, 2023 | $-0.15 | $-14.25 | -9400.0% | ✗ MISS |
Q3 2023 | Aug 14, 2023 | $-11.25 | $-17.25 | -53.3% | ✗ MISS |
Q2 2023 | May 15, 2023 | $-21.25 | $-20.25 | +4.7% | ✓ BEAT |
Q1 2023 | Mar 30, 2023 | $1.75 | $-18.25 | -1142.9% | ✗ MISS |
Q4 2022 | Nov 9, 2022 | $-56.25 | $-56.25 | 0.0% | = MET |
Q3 2022 | Aug 11, 2022 | $-68.75 | $-56.25 | +18.2% | ✓ BEAT |
Q2 2022 | May 11, 2022 | $-56.25 | $-62.50 | -11.1% | ✗ MISS |
Q1 2022 | Mar 31, 2022 | $-56.25 | $-50.00 | +11.1% | ✓ BEAT |
Q4 2021 | Nov 15, 2021 | $-56.25 | $-50.00 | +11.1% | ✓ BEAT |
Q3 2021 | Aug 12, 2021 | $-50.00 | $-56.25 | -12.5% | ✗ MISS |
Q2 2021 | May 6, 2021 | $-50.00 | $-37.50 | +25.0% | ✓ BEAT |
Q1 2021 | Mar 9, 2021 | $-1.50 | $-50.00 | -3233.3% | ✗ MISS |
Latest News
Frequently Asked Questions about TRVN
What is TRVN's current stock price?
What is the analyst price target for TRVN?
What sector is Trevena, Inc. in?
What is TRVN's market cap?
Does TRVN pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to TRVN for comparison